[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100584356":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":10,"responsibleParty":21,"collaborators":10,"id":25,"slug":26,"hasResults":27,"nctId":28,"briefTitle":29,"officialTitle":30,"acronym":31,"eligibilityCriteria":32,"healthyVolunteers":33,"sex":34,"minAge":35,"maxAge":10,"enrollmentInfo":36,"targetDuration":10,"studyType":39,"phases":10,"briefSummary":40,"conditions":41,"keywords":44,"overallStatus":49,"whyStopped":10,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":10},{"fullName":5,"class":6},"University of Campania Luigi Vanvitelli","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Healthy subjects",null,"The control group consisted of unrelated age- and sex-matched healthy subjects as volunteer blood donors with no evidence of any ECG abnormalities, inherited arrhythmia, genetic cardiomyopathy, and no history of ventricular arrhythmia, unexplained syncope, unexplained sudden cardiac arrest\u002F death.",{"label":13,"type":10,"description":14,"interventionNames":10},"Brugada patients","Brugada syndrome was confirmed when the 12-lead ECG showed ST-segment elevation with a type-1 morphology of ≥2 mm in ≥1 right precordial lead either spontaneously or after a provocative drug test (intravenous administration of a Class I antiarrhythmic) in the absence of any structural heart disease.",[16],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"Giuditta Benincasa, PhD","CONTACT","0815667916","giuditta.benincasa@unicampania.it",{"type":22,"investigatorFullName":23,"investigatorTitle":24,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Giuditta Benincasa","Principal Investigator","100584356","dna-methylation-in-brugada-syndrome-and-risk-of-sudden-cardiac-death-100584356",false,"NCT06888271","DNA Methylation in Brugada Syndrome and Risk of Sudden Cardiac Death","DNA Methylation in Brugada Syndrome and Risk of Sudden Cardiac Death (ANDROMEDA)","ANDROMEDA","Inclusion Criteria:\n\n* Brugada syndrome was confirmed when the 12-lead ECG showed ST-segment elevation with a type-1 morphology of ≥2 mm in ≥1 right precordial lead either spontaneously or after a provocative drug test (intravenous administration of a Class I antiarrhythmic) in the absence of any structural heart disease.\n* \\>18 years\n* Unrelated patients\n\nExclusion Criteria:\n\n* Related patients\n* Not type 1 Br patter",true,"ALL","18 Years",{"count":37,"type":38},10,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to evaluate if there are differences in DNA methylation of peripheral blood in patients with Brugada syndrome and healthy subjects. The main question it aims to answer is:\n\nDoes DNA methylation changes distinguish Brugada patients from healthy controls?\n\nDoes DNA methylation changes distinguish Brugada patients with high versus low risk of sudden cardiac death?",[42,43],"Brugada Syndrome","Sudden Cardiac Death Due to Cardiac Arrhythmia",[45,46,47,48],"DNA methylation","Liquid biopsy","Sudden cardiac death","Brugada syndrome","NOT_YET_RECRUITING","2025-03-20",{"date":52,"type":53},"2025-03-24","ACTUAL",{"date":55,"type":38},"2025-05",{"date":57,"type":38},"2026-07",{"name":5,"class":6}]